{
    "2019-06-26": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Sector Laggards: Utilities, Healthcare",
                "features": {
                    "keywords": [
                        "Utilities",
                        "Healthcare",
                        "Laggards"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "utilities",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Lilly's Heart Drug Snags Fast Track Designation; Type 2 Diabetes Drug Found Effective At Higher Doses",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Heart Drug",
                        "Fast Track",
                        "Type 2 Diabetes",
                        "Effective",
                        "Higher Doses"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Regeneron-Sanofi",
                        "Vermillion",
                        "PDL BioPharma",
                        "CFO Depart"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Lilly's AWARD-11 trial studying higher investigational doses of TrulicityÂ® (dulaglutide) demonstrated superiority in A1C reduction in people with type 2 diabetes",
                "features": {
                    "keywords": [
                        "Lilly",
                        "AWARD-11",
                        "Trulicity",
                        "Dulaglutide",
                        "Superiority",
                        "A1C Reduction",
                        "Type 2 Diabetes"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure",
                "features": {
                    "keywords": [
                        "FDA",
                        "Fast Track",
                        "Empagliflozin",
                        "Chronic Heart Failure"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}